# Ostial Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ostial

- Industry: Medical Devices & Equipment
- Headquarters: Mountain View, US
- Website: www.ostialcorp.com
- Total disclosed funding: $7.7M
- Latest round: Series C (Sep 1, 2022)
- Investors on record: 2

## About

Ostial Corporation, now known as Verge Medical, focuses on innovative solutions for vascular interventions, enhancing patient care through advanced products that improve vascular access and management techniques.Founded in 2009 in Mountain View, US, Ostial Corporation operates under the name Verge Medical, specializing in vascular intervention solutions. The company raised USD 7.72 mn in Series C funding on September 1, 2022, led by Delos Capital Partners, with participation from AMED Ventures. Verge Medical has completed 2 deals to date, achieving a total funding of USD 7.72 mn and a current valuation of USD 15.88 mn.Verge Medical specializes in innovative solutions for vascular interventions, aimed at addressing critical gaps in patient care. The company’s core offerings focus on improving vascular access and management techniques, delivering advanced products designed to enhance patient outcomes through faster recovery times and more efficient treatment processes. Their products are primarily marketed to healthcare providers in North America and select European markets, targeting interventional radiologists, vascular surgeons, and cardiologists.Verge Medical generates revenue through direct sales of its medical devices and products to healthcare providers. Their business model centers around B2B transactions, selling directly to hospitals and outpatient surgery centers. Revenue is derived from individual product sales and potential partnerships with larger healthcare networks that incorporate Verge Medical's offerings into their treatment protocols.Verge Medical plans to utilize the USD 7.72 mn raised in Series C funding to accelerate the commercialization and pipeline expansion of its novel FLASH™ Aorto-Ostial Angioplasty System. The company aims to design and launch new products while expanding into new markets, targeting regions in Europe and North America by the end of 2024.

## Funding rounds

- Series C, Sep 1, 2022, $7.7M — Delos Capital Partners, AMED Ventures

## Investors

- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series C
- AMED Ventures (https://capitalatlas.ai/funds/amed-ventures) — Series C